Long-term Follow-up of Measles Antibodies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00168571 |
Recruitment Status :
Completed
First Posted : September 15, 2005
Last Update Posted : September 22, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Measles | Biological: Measles vaccine | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Enrollment : | 1960 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau |
Study Start Date : | March 2002 |
Actual Study Completion Date : | January 2007 |
- Measles antibody level

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 10 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: Children participating in the Two-dose trial (Non-Specific Effects of Standard Titre Measles Vaccination, Protocol ID: IC18-CT95-0011-Twodose1)
Exclusion Criteria: Severe illness requiring hospitalisation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168571
Guinea-Bissau | |
Bandim Health Project | |
Bissau, Apartado 861, Guinea-Bissau, 1004 Bissau Codex |
Study Director: | PETER AABY, MSc, Dr Med | Bandim Health Project | |
Principal Investigator: | MAY-LILL GARLY, PHD, DTM&H | Bandim Health Project |
ClinicalTrials.gov Identifier: | NCT00168571 |
Other Study ID Numbers: |
LTAB-2288/2292-Twodose1 NOVO-2288 Lægevidenskabens Fremme-2292 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | September 22, 2011 |
Last Verified: | September 2006 |
Measles vaccine Measles Measles antibodies Immunisation |
Low income country Guinea-Bissau Bandim Health Project Measles antibody level |
Measles Morbillivirus Infections Paramyxoviridae Infections |
Mononegavirales Infections RNA Virus Infections Virus Diseases |